Allergy Therapeutics (AGY)

 

Latest News

Holdings in Company

RNS Number: 5221B Allergy Therapeutics PLC 10 January 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Allergy The...

Allergy Therapeutics completes recruitment for clinical study

Allergy Therapeutics said recruitment of the group's phase III clinical trial with PQ Birch (PQBirch301) has been completed...

PQ Birch Phase III trial completes recruitment

RNS Number: 2889B Allergy Therapeutics PLC 09 January 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") PQ Birch Phase III clinical trial completes recruitment 9 January 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces that recruitment of the Gro...

Allergy Therapeutics co-development agreement with Ergomed

Allergy Therapeutics has entered into a co-development collaboration agreement with Ergomed for the clinical developme...

All News

DateHeadlineSource
03-08-12Markets: FTSE 100 climbs higher on FridayInteractive Investor
18-04-12Markets: FTSE 100 uncertain on WednesdayInteractive Investor
06-12-11Markets: FTSE 100 flat on TuesdayInteractive Investor
26-04-11Markets: Manufacturing data lifts FTSE 100Interactive Investor
26-04-11FDA approval lifts shares in Allergy TherapeuticsInteractive Investor
28-03-11Markets: FTSE 100 trims gains on MondayInteractive Investor

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account